Sarepta Therapeutics (SRPT) has drawn investor attention after its shares closed at US$20.64, with recent returns showing mixed short term moves, a monthly gain, and a decline over the past three ...
LOS ANGELES, July 31, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations ...
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
As of December 6, 2025, the average one-year price target for Sarepta Therapeutics is $29.96/share. The forecasts range from a low of $5.05 to a high of $194.25. The average price target represents an ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...
The average one-year price target for Sarepta Therapeutics (NasdaqGS:SRPT) has been revised to $22.48 / share. This is a decrease of 10.97% from the prior estimate of $25.25 dated April 7, 2026. The ...
Hosted on MSN
SRPT stock tumbles 12% on lackluster preliminary revenue numbers due to Elevidys safety concerns
・Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” ・Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns ...
Sarepta Therapeutics is trading around $19 in extended hours following the FDA’s decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory ...
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results